A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Dana-Farber Cancer Institute, Boston, Massachusetts

Washington University School of Medicine, St Louis, Missouri

Fred Hutchinson Cancer Center, Seattle, Washington